Osteoporosis International

, Volume 14, Issue 5, pp 437–441

Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate

  • Nelson B. Watts
  • Robert Lindsay
  • Zhengqing Li
  • Chandrasekhar Kasibhatla
  • Jacques Brown
Original Article


Placebo controls are essential to assess anti-fracture efficacy of new osteoporosis therapies, but inclusion of a placebo arm in a subsequent clinical trial may be limited by practical or ethical considerations; in these cases, use of an historical control may be appropriate. A recent active-controlled study of risedronate 35 mg once a week demonstrated that this regimen produces increases in bone mineral density (BMD) that are comparable to those seen with the risedronate 5 mg daily dose, which has proven anti-fracture efficacy. To assess the anti-fracture efficacy of this new regimen, we have analyzed the fracture data collected in an active controlled study of risedronate dosing regimens (the Once-a-Week study) using matched historical control data from previous placebo-controlled trials. Women in the Once-a-Week study were matched for age, years since menopause, BMD, and prevalent vertebral fracture status, with placebo patients in the Vertebral Efficacy of Risedronate Therapy (VERT) trials forming an historical placebo group. We also constructed an historical active treatment group from the 5 mg daily arm of the VERT trials for comparison with the 5 mg daily and 35 mg once weekly treatment groups in the Once-a-Week study. Data were obtained from the risedronate 5 mg daily group (n=480) and 35 mg once-a-week group (n=485) in the Once-a-Week study and historical control groups representing daily placebo patients (n=114, matched from 993) and risedronate 5 mg daily patients (n=120; matched from 990) in the VERT studies. Patients received calcium supplementation (1000 mg daily); vitamin D was given if baseline serum 25-hydroxyvitamin D levels were low. Over 1 year, new vertebral fracture risk in the 35 mg once-a-week group was reduced by 77% relative to the historical placebo group (1.2% versus 5.0%; RR 0.23; 95% CI, 0.54 to 0.91, P=0.018), similar to the 1-year risk reduction observed in the VERT trials of risedronate 5 mg daily (61–65%). The incidence of new vertebral fractures in the three active treatment groups was similar: 1.7% in the historical risedronate 5 mg group, 1.5% in the risedronate 5 mg daily group from the Once-a-Week study, and 1.2% in the 35 mg once-a-week group. Risedronate 35 mg once a week appears as effective as the 5 mg daily dose in reducing the risk of new vertebral fractures in the first year of treatment. The use of appropriate historical control data provides an approach to the assessment of fracture effects in osteoporosis trials for which placebo-controlled data are not available.


Postmenopausal osteoporosis Risedronate Vertebral fracture Historical control 


  1. 1.
    Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344–1352Google Scholar
  2. 2.
    Reginster J, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83–91Google Scholar
  3. 3.
    Cohen S, Levy RM, Keller M et al. (1999) Risedronate therapy prevents corticosteroid-induced bone loss. Arthr Rheum 42:2309–2318Google Scholar
  4. 4.
    Reid DM, Hughes RA, Laan R et al. (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 15:1006–1013Google Scholar
  5. 5.
    Wallach S, Cohen S, Reid DM et al. (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67:277–285Google Scholar
  6. 6.
    Brown J, Kendler D, McClung MR et al. (2002) The efficacy and tolerability of risedronate once a week for the treatment of osteoporosis. Calcif Tissue Int 71:103–111Google Scholar
  7. 7.
    Cleophas TJ, Zwinderman AH (2000) Limitations of randomized clinical trials. Proposed alternative designs. Clin Chem Lab Med 38:1217–1223Google Scholar
  8. 8.
    Rosner F (1987) The ethics of randomized clinical trials. Am J Med 82:283–290Google Scholar
  9. 9.
    Cummings SR, Black DM, Thompson ED et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 280:2077–2082Google Scholar
  10. 10.
    Ettinger B, Black DM, Mitlak BH et al. (1999) Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282:637–645Google Scholar
  11. 11.
    Black DM, Cummings SR, Karpf DB et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541Google Scholar
  12. 12.
    Chesnut CH, III, Silverman S, Andriano K et al. (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 109:267–276Google Scholar
  13. 13.
    Gehan EA (1984) The evaluation of therapies: historical control studies. Stat Med 3:315–324Google Scholar
  14. 14.
    Pocock SJ (1976) The combination of randomized and historical controls in clinical trials. J Chron Dis 29:175–188Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2003

Authors and Affiliations

  • Nelson B. Watts
    • 1
    • 5
  • Robert Lindsay
    • 2
  • Zhengqing Li
    • 3
  • Chandrasekhar Kasibhatla
    • 3
  • Jacques Brown
    • 4
  1. 1.University of CincinnatiCincinnatiUSA
  2. 2.Helen Hayes HospitalWest HaverstrawUSA
  3. 3.Procter & Gamble PharmaceuticalsCincinnatiUSA
  4. 4.Le Centre de recherche du CHULLaval UniversitySainte-FoyCanada
  5. 5.University of Cincinnati Bone Health and Osteoporosis CenterCincinnatiUSA

Personalised recommendations